ECULIZUMAB-AEEB | B761333 | AMGEN INC
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | May. 28, 2036 | Active | Computed |
| 1-Year Interchangeable | Nov. 28, 2025 | Expired | Purple Book |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12378521(manufacturing) · relevance 75/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Approved Biosimilars
Top 50 of 262 AI-discovered patents by relevance.
No patent or exclusivity listings for this strength.